CJC-1295

What people use it for

• Raising growth hormone and IGF-1
• Body composition, recovery and sleep (popular use)

What CJC-1295 does in the body

A modified GHRH analog. The "DAC" (drug affinity complex) version binds to albumin in the blood, extending its action to several days; the version without DAC (Mod GRF 1-29) is short-acting. Both stimulate pituitary growth hormone release.

Strength of evidence

Limited: small early-phase human studies showed sustained rises in GH and IGF-1; clinical development was discontinued.

Look up the evidence

• Reviews on PubMed: Summaries of the published research
• Clinical trials on PubMed: Published studies in people
• ClinicalTrials.gov: Registered trials, past and ongoing

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

• Injection-site reactions
• Flushing, headache
• Water retention
• Theoretical risks of chronically elevated GH/IGF-1

Who should avoid it or take extra care

• Pregnant or breastfeeding
• Active or past cancer
• Diabetes (raised GH and IGF-1 can increase blood sugar)
• Competitive athletes (prohibited by WADA)

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Not approved. Prohibited in sport by WADA.

How it's taken

Route: Injection under the skin

How long it lasts (half-life): About 6–8 days with DAC; about 30 minutes without

Storage

Unreconstituted (powder) vials are usually kept refrigerated or frozen and away from light. Once mixed with bacteriostatic water, keep refrigerated and do not freeze; follow the supplier's stated beyond-use date.

Mixing guides

How much water to add and what each syringe mark holds, worked out for your own dose:

• 2 mg vial
• 5 mg vial

Found in these stacks

• CJC-1295 + Ipamorelin: Two growth hormone releasers that work through different pathways, often sold pre-mixed.